Defunct Company
Total Trials
4
As Lead Sponsor
As Collaborator
0
Total Enrollment
416
NCT01166984
AB103 Peptide Antagonist in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2010
Completion: Jun 30, 2011
NCT01417780
Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients
Phase: Phase 2
Start: Dec 31, 2011
Completion: Sep 30, 2012
NCT02469857
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
Phase: Phase 3
Start: Dec 1, 2015
Completion: Oct 18, 2019
NCT03403751
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
Start: May 24, 2018
Completion: Dec 14, 2019